These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21192147)

  • 1. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable.
    Rabinowitz J; Napryeyenko O; Burba B; Martinez G; Neznanov NG; Fischel T; Baylé FJ; Cavallaro R; Smeraldi E; Schreiner A
    J Clin Psychopharmacol; 2011 Feb; 31(1):75-81. PubMed ID: 21192147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
    Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.
    Lloyd K; Latif MA; Simpson S; Shrestha KL
    Hum Psychopharmacol; 2010 Apr; 25(3):243-52. PubMed ID: 20373476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
    Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
    Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
    Lee MS; Ko YH; Lee SH; Seo YJ; Kim SH; Joe SH; Han CS; Lee JH; Jung IK
    Hum Psychopharmacol; 2006 Aug; 21(6):399-407. PubMed ID: 16915580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
    J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia.
    Lin CH; Kuo CC; Chou LS; Chen YH; Chen CC; Huang KH; Lane HY
    J Clin Psychopharmacol; 2010 Oct; 30(5):518-25. PubMed ID: 20814315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
    Schmauss M; Sacchetti E; Kahn JP; Medori R
    Int Clin Psychopharmacol; 2007 Mar; 22(2):85-92. PubMed ID: 17293708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.